Rhythm Pharmaceuticals, Inc.
RYTMNasdaqCIK 1649904HealthcareFiscal year ends Dec 31
Reports and events: 174 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-04-0318:18 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-086172 |
| 2024-04-0117:25 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-041970 |
| 2024-03-2017:51 ET | SC 13D | Ownership report, active investor | 0001193125-24-072901 |
| 2024-02-2916:46 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-24-029417 |
| 2024-02-2916:05 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001558370-24-002181 |
| 2024-02-2207:01 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-026303 |
| 2024-01-0407:15 ET | 8-K | 7.01 Regulation FD disclosure | 0001104659-24-001141 |
| 2024-01-0407:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events | 0001104659-24-001139 |
| 2023-12-1816:16 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-23-126873 |
| 2023-12-0616:30 ET | 8-K | 8.01 Other events | 0001104659-23-123990 |
| 2023-11-0816:30 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001558370-23-018291 |
| 2023-11-0707:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-114996 |
| 2023-08-2116:30 ET | 8-K | 8.01 Other events | 0001104659-23-093945 |
| 2023-08-0807:32 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-23-088604 |
| 2023-08-0317:22 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-23-087375 |
| 2023-08-0116:27 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001558370-23-012739 |
| 2023-08-0107:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-086034 |
| 2023-06-2216:47 ET | 8-K | 5.07 Shareholder vote results | 0001104659-23-073809 |
| 2023-05-0216:30 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001558370-23-007675 |
| 2023-05-0207:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-054774 |
| 2023-04-2717:08 ET | DEF 14A | Proxy statementPeriod 2023-06-21 | 0001104659-23-051469 |
| 2023-03-2918:51 ET | SC 13D/A | Ownership report, active investor, amended | 0001072613-23-000270 |
| 2023-03-1014:46 ET | 8-K | 8.01 Other events | 0001104659-23-031097 |
| 2023-03-0117:27 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001558370-23-002613 |
| 2023-03-0107:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-026995 |
| 2023-01-0916:06 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-23-002258 |
| 2022-11-0814:06 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001558370-22-016818 |
| 2022-11-0807:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-115675 |
| 2022-11-0316:55 ET | 8-K | 1.02 Termination of a material agreement | 0001104659-22-114457 |
| 2022-09-1516:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-22-100433 |
| 2022-08-0316:18 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0001558370-22-011888 |
| 2022-08-0207:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-084960 |
| 2022-06-1617:11 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-22-071971 |
| 2022-06-1016:30 ET | 8-K | 5.07 Shareholder vote results | 0001104659-22-070152 |
| 2022-05-0315:27 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0001558370-22-006790 |
| 2022-05-0307:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-055004 |
| 2022-04-2816:40 ET | DEF 14A | Proxy statementPeriod 2022-06-08 | 0001104659-22-052338 |
| 2022-04-0608:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-22-043012 |
| 2022-03-0115:53 ET | 10-K | Annual reportPeriod 2021-12-31 | 0001558370-22-002543 |
| 2022-03-0115:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-028609 |
| 2021-12-0817:08 ET | 8-K | 1.01 Entry into a material agreement | 0001104659-21-147685 |
| 2021-11-0214:13 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001558370-21-014043 |
| 2021-11-0207:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-21-132636 |
| 2021-09-0216:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001104659-21-112483 |
| 2021-08-0315:41 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001558370-21-009963 |
| 2021-08-0307:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-21-099155 |
| 2021-06-1416:04 ET | 8-K | 5.07 Shareholder vote results | 0001104659-21-080758 |
| 2021-05-0308:54 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-21-059747 |
| 2021-05-0308:36 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001558370-21-005475 |
| 2021-04-2716:06 ET | DEF 14A | Proxy statementPeriod 2021-06-09 | 0001104659-21-055591 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 3, 2026, 19:08 ET. Listed shows no prices and gives no investment advice.